Cargando…

Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study

BACKGROUND: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pamidi, Sushmita, Chapotot, Florian, Wroblewski, Kristen, Whitmore, Harry, Polonsky, Tamar, Tasali, Esra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792375/
https://www.ncbi.nlm.nih.gov/pubmed/32998624
http://dx.doi.org/10.1161/JAHA.120.016871
_version_ 1783633791417319424
author Pamidi, Sushmita
Chapotot, Florian
Wroblewski, Kristen
Whitmore, Harry
Polonsky, Tamar
Tasali, Esra
author_facet Pamidi, Sushmita
Chapotot, Florian
Wroblewski, Kristen
Whitmore, Harry
Polonsky, Tamar
Tasali, Esra
author_sort Pamidi, Sushmita
collection PubMed
description BACKGROUND: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP). To date, no prior study has assessed the effect of CPAP treatment on daytime resting heart rate, a strong predictor of adverse cardiovascular outcomes and mortality. METHODS AND RESULTS: We conducted a randomized controlled study in 39 participants with OSA and prediabetes, who received either in‐laboratory all‐night (ie, optimal) CPAP or an oral placebo for 2 weeks. During daytime, participants continued daily activities outside the laboratory. Resting heart rate was continuously assessed over 19 consecutive days and nights using an ambulatory device consisting of a single‐lead ECG and triaxis accelerometer. Compared with placebo, CPAP reduced daytime resting heart rate (treatment difference, −4.1 beats/min; 95% CI, −6.5 to −1.7 beats/min; P=0.002). The magnitude of reduction in daytime resting heart rate after treatment significantly correlated with the magnitude of decrease in plasma norepinephrine, a marker of sympathetic activity (r=0.44; P=0.02), and the magnitude of decrease in OSA severity (ie, apnea‐hypopnea index [r=0.48; P=0.005], oxygen desaturation index [r=0.50; P=0.003], and microarousal index [r=0.57; P<0.001]). CONCLUSIONS: This proof‐of‐concept randomized controlled study demonstrates, for the first time, that CPAP treatment, when optimally used at night, reduces resting heart rate during the day, and therefore has positive cardiovascular carry over effects. These findings suggest that better identification and treatment of OSA may have important clinical implications for cardiovascular disease prevention. REGISTRATION: URL: https:/// www.clini​caltr​ials.gov; Unique identifier: NCT01156116.
format Online
Article
Text
id pubmed-7792375
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77923752021-01-15 Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study Pamidi, Sushmita Chapotot, Florian Wroblewski, Kristen Whitmore, Harry Polonsky, Tamar Tasali, Esra J Am Heart Assoc Brief Communication BACKGROUND: It has been widely recognized that obstructive sleep apnea (OSA) is linked to cardiovascular disease. Yet, randomized controlled studies failed to demonstrate a clear cardiovascular benefit from OSA treatment, mainly because of poor adherence to continuous positive airway pressure (CPAP). To date, no prior study has assessed the effect of CPAP treatment on daytime resting heart rate, a strong predictor of adverse cardiovascular outcomes and mortality. METHODS AND RESULTS: We conducted a randomized controlled study in 39 participants with OSA and prediabetes, who received either in‐laboratory all‐night (ie, optimal) CPAP or an oral placebo for 2 weeks. During daytime, participants continued daily activities outside the laboratory. Resting heart rate was continuously assessed over 19 consecutive days and nights using an ambulatory device consisting of a single‐lead ECG and triaxis accelerometer. Compared with placebo, CPAP reduced daytime resting heart rate (treatment difference, −4.1 beats/min; 95% CI, −6.5 to −1.7 beats/min; P=0.002). The magnitude of reduction in daytime resting heart rate after treatment significantly correlated with the magnitude of decrease in plasma norepinephrine, a marker of sympathetic activity (r=0.44; P=0.02), and the magnitude of decrease in OSA severity (ie, apnea‐hypopnea index [r=0.48; P=0.005], oxygen desaturation index [r=0.50; P=0.003], and microarousal index [r=0.57; P<0.001]). CONCLUSIONS: This proof‐of‐concept randomized controlled study demonstrates, for the first time, that CPAP treatment, when optimally used at night, reduces resting heart rate during the day, and therefore has positive cardiovascular carry over effects. These findings suggest that better identification and treatment of OSA may have important clinical implications for cardiovascular disease prevention. REGISTRATION: URL: https:/// www.clini​caltr​ials.gov; Unique identifier: NCT01156116. John Wiley and Sons Inc. 2020-10-01 /pmc/articles/PMC7792375/ /pubmed/32998624 http://dx.doi.org/10.1161/JAHA.120.016871 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communication
Pamidi, Sushmita
Chapotot, Florian
Wroblewski, Kristen
Whitmore, Harry
Polonsky, Tamar
Tasali, Esra
Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
title Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
title_full Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
title_fullStr Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
title_full_unstemmed Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
title_short Optimal Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Reduces Daytime Resting Heart Rate in Prediabetes: A Randomized Controlled Study
title_sort optimal continuous positive airway pressure treatment of obstructive sleep apnea reduces daytime resting heart rate in prediabetes: a randomized controlled study
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792375/
https://www.ncbi.nlm.nih.gov/pubmed/32998624
http://dx.doi.org/10.1161/JAHA.120.016871
work_keys_str_mv AT pamidisushmita optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy
AT chapototflorian optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy
AT wroblewskikristen optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy
AT whitmoreharry optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy
AT polonskytamar optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy
AT tasaliesra optimalcontinuouspositiveairwaypressuretreatmentofobstructivesleepapneareducesdaytimerestingheartrateinprediabetesarandomizedcontrolledstudy